Clinical Performance Characteristics of a Molecular IVD-cleared Multiplex Respiratory Panel for SARS-COV-2, Influenza A, Influenza B, and Respiratory Syncytial Virus

Attend this 33-minute webinar to learn about the clinical performance characteristics of a molecular IVD-cleared multiplex respiratory panel for detecting SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus. Discover how respiratory tract infections caused by multiple pathogens present overlapping signs that make diagnosis challenging without targeted, sensitive molecular testing. Explore the clinical evaluation results of the TaqPath COVID-19, Flu A, Flu B, RSV Select Panel, a multiplex real-time PCR test designed for detection and differentiation of these key respiratory pathogens. Gain insights from Dr. Harita Veereshlingam, a Staff Scientist at Thermo Fisher Scientific with over 17 years of experience in the life sciences industry, who holds a Ph.D. in Molecular Biology and has led numerous clinical validation studies for IVD devices including 510(k), IVDR, and CDSCO submissions. Learn about her expertise in clinical trials, regulatory compliance, and program management as she presents findings that advance reliable molecular diagnostic products to improve diagnosis and treatment timelines. Participate in a live Q&A session to deepen your understanding of multiplex respiratory testing technologies and their clinical applications.